These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 24565367)

  • 1. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.
    Herrmann N; Lanctôt KL; Hogan DB
    Alzheimers Res Ther; 2013 Jul; 5(Suppl 1):S5. PubMed ID: 24565367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Burns A;
    J Psychopharmacol; 2011 Aug; 25(8):997-1019. PubMed ID: 21088041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.
    Smith EE; Barber P; Field TS; Ganesh A; Hachinski V; Hogan DB; Lanctôt KL; Lindsay MP; Sharma M; Swartz RH; Ismail Z; Gauthier S; Black SE
    Alzheimers Dement (N Y); 2020; 6(1):e12056. PubMed ID: 33209971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.
    Ismail Z; Black SE; Camicioli R; Chertkow H; Herrmann N; Laforce R; Montero-Odasso M; Rockwood K; Rosa-Neto P; Seitz D; Sivananthan S; Smith EE; Soucy JP; Vedel I; Gauthier S;
    Alzheimers Dement; 2020 Aug; 16(8):1182-1195. PubMed ID: 32725777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressants for agitation and psychosis in dementia.
    Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
    Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians.
    Moore A; Patterson C; Lee L; Vedel I; Bergman H;
    Can Fam Physician; 2014 May; 60(5):433-8. PubMed ID: 24829003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Sink KM; Holden KF; Yaffe K
    JAMA; 2005 Feb; 293(5):596-608. PubMed ID: 15687315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia.
    Herrmann N; Ismail Z; Collins R; Desmarais P; Goodarzi Z; Henri-Bhargava A; Iaboni A; Kirkham J; Massoud F; Moser A; Silvius J; Watt J; Seitz D
    Alzheimers Dement (N Y); 2022; 8(1):e12099. PubMed ID: 35128025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.
    Van Leeuwen E; Petrovic M; van Driel ML; De Sutter AI; Vander Stichele R; Declercq T; Christiaens T
    Cochrane Database Syst Rev; 2018 Apr; 3(3):CD007726. PubMed ID: 29605970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
    Buckley JS; Salpeter SR
    Drugs Aging; 2015 Jun; 32(6):453-67. PubMed ID: 25941104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.